Ginkgo and Merck collaborate to improve biologic manufacturing 

Ginkgo Bioworks and Merck have collaborated to improve the production of biologics. 

Ginkgo will apply its expertise and capabilities in cell engineering, ultra high-throughput multiplexed screening, protein characterisation and process optimisation to improve production efficiency and increase yields.  

“We’re thrilled to leverage our platform to improve the production of biologics in collaboration with Merck,” said Jason Kelly, CEO and Co-Founder of Ginkgo Bioworks. “In particular, we will utilise some of our unique capabilities, such as automated protocols to do predictive ultra high-throughput multiplexed screening, product characterisation and process optimisation. It’s exciting for our team to drive impactful and technically innovative work, and to do so shoulder-to-shoulder with our counterparts at Merck.” 

“At Merck, we are always seeking new and innovative ways to optimise process efficiency while maintaining product integrity,” said Dr Michael Kress, Senior Vice President, Development Sciences and Clinical Supply, Merck Research Laboratories.  

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free